Literature DB >> 2904008

Differences in relative efficiency of nebulisers for pentamidine administration.

M J O'Doherty1, S Thomas, C Page, D Barlow, C Bradbeer, T O Nunan, N T Bateman.   

Abstract

The study compared the pulmonary deposition of nebulised pentamidine when inhaled by way of different nebuliser systems by nine human-immunodeficiency-virus-positive patients with a history of previous Pneumocystis carinii pneumonia. Pentamidine, 50 mg or 300 mg, mixed with technetium-99m-labelled human serum albumin in a total volume of 3 ml, was administered by way of three jet nebulisers (System 22', 'System 22 Mizer', and 'Respigard II') operated with a gas flow of 6 l/min, and one ultrasound nebuliser ('Pulmosonic'). Pulmonary and non-pulmonary isotope deposition was measured for each apparatus and adverse effects and lung function tests were recorded. For both doses of pentamidine, the system 22 mizer produced the largest pulmonary isotope deposition and it was completed in the shortest time. Oropharyngeal and gastric deposition were least with the respigard II, which also caused the fewest adverse effects. The adverse effects were greatest with the system 22 mizer and pulmosonic and the higher pentamidine dose, which also caused significant reductions in measurements of pulmonary function. It is concluded that either the system 22 mizer or the respigard II should be used to administer nebulised pentamidine.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2904008     DOI: 10.1016/s0140-6736(88)92894-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  19 in total

Review 1.  Pneumocystis carinii pneumonia.

Authors:  S Thomas; M O'Doherty; N Bateman
Journal:  BMJ       Date:  1990-01-27

Review 2.  AIDS and the lung. 7. Treatment of lung disease in patients with the acquired immune deficiency syndrome.

Authors:  D M Mitchell; M A Johnson
Journal:  Thorax       Date:  1990-03       Impact factor: 9.139

3.  Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in mice.

Authors:  J Conley; H Yang; T Wilson; K Blasetti; V Di Ninno; G Schnell; J P Wong
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

4.  Nebulisers for patients with HIV infection and AIDS.

Authors:  R F Miller; M J O'Doherty
Journal:  Thorax       Date:  1997-04       Impact factor: 9.139

5.  Compliance and laboratory data predict relapse rate of Pneumocystis carinii pneumonia during prophylaxis with aerosol pentamidine.

Authors:  M Opravil; R Weber; B Ledergerber; R Speich; W Siegenthaler; R Lüthy
Journal:  Klin Wochenschr       Date:  1990-04-17

6.  Relapse of pneumocystis pneumonia in the upper lobes during aerosol pentamidine prophylaxis.

Authors:  M J O'Doherty; S H Thomas; N T Bateman
Journal:  Thorax       Date:  1989-12       Impact factor: 9.139

Review 7.  Inhaled pentamidine. An overview of its pharmacological properties and a review of its therapeutic use in Pneumocystis carinii pneumonia.

Authors:  J P Monk; P Benfield
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

Review 8.  Pentamidine. A risk-benefit analysis.

Authors:  B Wispelwey; R Pearson
Journal:  Drug Saf       Date:  1990 May-Jun       Impact factor: 5.606

Review 9.  Aerosol therapy in AIDS.

Authors:  S P Newman; A K Simonds
Journal:  Lung       Date:  1990       Impact factor: 2.584

10.  Pulmonary deposition of nebulised pentamidine isethionate: effect of nebuliser type, dose, and volume of fill.

Authors:  M O'Doherty; S Thomas; C Page; C Bradbeer; T Nunan; N Bateman
Journal:  Thorax       Date:  1990-06       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.